

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 January 2023 (19.01.2023)



(10) International Publication Number
WO 2023/287590 A1

(51) International Patent Classification:

C07K 16/24 (2006.01) *A61P 37/00* (2006.01)
A61K 39/395 (2006.01) *A61K 39/00* (2006.01)
A61P 17/00 (2006.01)

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2022/035663

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(22) International Filing Date:

30 June 2022 (30.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(30) Priority Data:

21382645.6 16 July 2021 (16.07.2021) EP
22382098.6 07 February 2022 (07.02.2022) EP

(71) Applicant: **DERMIRA, INC.** [US/US]; LILLY CORPO-
RATE CENTER, Indianapolis, Indiana 46285 (US).

(72) Inventors: **AGELL GIMENO, Helena**; c/o ELI LILLY
AND COMPANY, P.O. Box 6288, Indianapolis, Indiana
46206-6288 (US). **ARMENGOL TUBAU, Clara**; c/o ELI
LILLY AND COMPANY, P.O. Box 6288, Indianapolis, In-
diana 46206-6288 (US). **GARCIA GIL, Maria Esther**; c/o
ELI LILLY AND COMPANY, P.O. Box 6288, Indianapo-
lis, Indiana 46206-6288 (US). **MAESO NAVAL, Silvia**;
c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indi-
anapolis, Indiana 46206-6288 (US).

(74) Agent: **GAO, Xiaoguang** et al.; ELI LILLY AND COM-
PANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288
(US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: IL-13 ANTIBODIES FOR THE TREATMENT OF ATOPIC DERMATITIS

(57) Abstract: Provided herein are methods, uses and pharmaceutical compositions of antibodies that bind human IL-13 ("anti-IL-13 antibodies") for treating atopic dermatitis or reducing pruritis associated with atopic dermatitis. Also provided herein are doses and dosing regimens for the methods and uses of anti-IL-13 antibodies for treating atopic dermatitis or reducing pruritis associated with atopic dermatitis.



WO 2023/287590 A1